Status:
COMPLETED
Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen
Lead Sponsor:
Uruk University
Conditions:
Breast Cancer
Endometrial Hyperplasia and Endometrial Cancers
Eligibility:
FEMALE
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn if metformin can reduce the increase in endometrial thickness caused by tamoxifen in women with estrogen-positive breast cancer taking tamoxifen for more th...
Eligibility Criteria
Inclusion
- Postmenopausal Female patients (amenorrhea ≥ 12 months).
- Histologically proven (Estrogen-positive) breast cancer.
- Completed all required surgery and/or chemotherapy (if indicated)
- On adjuvant tamoxifen for at least 1 year.
- Accepts to enroll in the study
Exclusion
- Refusing to enroll in the study
- Ongoing or History of: endometrial or ovarian malignancy
- Concurrent hormonal therapy that might affect endometrial thickness
- Concurrent Diabetes mellitus in which metformin is prescribed.
- Known hypersensitivity or severe intolerance to metformin
Key Trial Info
Start Date :
January 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07145827
Start Date
January 2 2024
End Date
July 1 2025
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baghdad Medical City / Department of Oncology
Baghdad, Baghdad Governorate, Iraq, 10045